問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

吳宗哲
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

61Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳宗哲

List

76Cases

2024-09-24 - 2029-12-31

Phase II

Active
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    MTAP-deleted NSCLC

  • Test Drug

    Tablets

Participate Sites
3Sites

Recruiting3Sites

2025-09-01 - 2027-05-31

Phase I/II

Active
A first-in-human dose escalation and expansion trial of BDC-4182 as a single agent in patients with advanced gastric and gastroesophageal cancer in stage 1/2.

  • Condition/Disease

    Advanced gastric cancer, advanced gastroesophageal cancer

  • Test Drug

    BDC-4182

Participate Sites
6Sites

Recruiting6Sites

2025-02-01 - 2030-12-31

Active
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    Tablets; Hard capsules

Participate Sites
4Sites

Recruiting4Sites

2025-02-11 - 2038-02-19

Phase III

Active
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

  • Condition/Disease

    Breast Cancer

  • Test Drug

    錠劑 錠劑 膠囊劑 錠劑 錠劑 錠劑

Participate Sites
8Sites

Recruiting8Sites

2023-11-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2021-04-01 - 2033-02-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-02-01 - 2026-10-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-12-01 - 2027-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2026-02-23 - 2030-03-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-08-20 - 2029-02-17

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4 5 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB